Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.

CONCLUSION: Within the limitations of this single-center retrospective analysis, clinically stable patients who were judged by clinicians to be eligible for continuing ICIs treatment post-DR derived apparent OS benefit than discontinuing counterpart.
PMID: 32518972 [PubMed - indexed for MEDLINE]

Source: Clinical Lung Cancer - October 8, 2020 Category: Cancer & Oncology Authors: Zhou H, Sun Y, Xiu W, Han J, Zhong L, Suo J, Wei H, Wang Y, Zhu J Tags: J Cancer Res Clin Oncol Source Type: research